nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—CYP2C8—Mometasone—systemic scleroderma	0.258	0.367	CbGbCtD
Carbinoxamine—CYP2C9—Leflunomide—systemic scleroderma	0.116	0.165	CbGbCtD
Carbinoxamine—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.103	0.146	CbGbCtD
Carbinoxamine—CYP2D6—Captopril—systemic scleroderma	0.0832	0.118	CbGbCtD
Carbinoxamine—CYP2C19—Prednisone—systemic scleroderma	0.0689	0.0979	CbGbCtD
Carbinoxamine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0417	0.0592	CbGbCtD
Carbinoxamine—CYP3A4—Prednisone—systemic scleroderma	0.0333	0.0473	CbGbCtD
Carbinoxamine—CYP2C9—cardial valve—systemic scleroderma	0.00641	0.608	CbGeAlD
Carbinoxamine—Agitation—Pentoxifylline—systemic scleroderma	0.00185	0.00648	CcSEcCtD
Carbinoxamine—Agranulocytosis—Captopril—systemic scleroderma	0.00182	0.00638	CcSEcCtD
Carbinoxamine—Diplopia—Lisinopril—systemic scleroderma	0.0018	0.00628	CcSEcCtD
Carbinoxamine—Palpitations—Pentoxifylline—systemic scleroderma	0.00178	0.00623	CcSEcCtD
Carbinoxamine—Sweating increased—Leflunomide—systemic scleroderma	0.00176	0.00616	CcSEcCtD
Carbinoxamine—Convulsion—Pentoxifylline—systemic scleroderma	0.00175	0.00611	CcSEcCtD
Carbinoxamine—Haemolytic anaemia—Mycophenolate mofetil—systemic scleroderma	0.00174	0.0061	CcSEcCtD
Carbinoxamine—Irritability—Lisinopril—systemic scleroderma	0.00171	0.006	CcSEcCtD
Carbinoxamine—Pollakiuria—Leflunomide—systemic scleroderma	0.00167	0.00584	CcSEcCtD
Carbinoxamine—Confusional state—Pentoxifylline—systemic scleroderma	0.00166	0.0058	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.00161	0.00563	CcSEcCtD
Carbinoxamine—Tachycardia—Pentoxifylline—systemic scleroderma	0.0016	0.00562	CcSEcCtD
Carbinoxamine—Pollakiuria—Mycophenolic acid—systemic scleroderma	0.00159	0.00557	CcSEcCtD
Carbinoxamine—Agranulocytosis—Azathioprine—systemic scleroderma	0.00159	0.00557	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.00159	0.00556	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Leflunomide—systemic scleroderma	0.00158	0.00552	CcSEcCtD
Carbinoxamine—Diplopia—Mycophenolate mofetil—systemic scleroderma	0.00157	0.00551	CcSEcCtD
Carbinoxamine—Anorexia—Pentoxifylline—systemic scleroderma	0.00157	0.00549	CcSEcCtD
Carbinoxamine—Hypotension—Pentoxifylline—systemic scleroderma	0.00154	0.00538	CcSEcCtD
Carbinoxamine—Sweating increased—Lisinopril—systemic scleroderma	0.00151	0.00529	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Mycophenolic acid—systemic scleroderma	0.00151	0.00527	CcSEcCtD
Carbinoxamine—Agranulocytosis—Leflunomide—systemic scleroderma	0.0015	0.00526	CcSEcCtD
Carbinoxamine—Tension—Captopril—systemic scleroderma	0.0015	0.00524	CcSEcCtD
Carbinoxamine—Urinary retention—Mycophenolate mofetil—systemic scleroderma	0.0015	0.00524	CcSEcCtD
Carbinoxamine—Insomnia—Pentoxifylline—systemic scleroderma	0.00149	0.0052	CcSEcCtD
Carbinoxamine—Nervousness—Captopril—systemic scleroderma	0.00148	0.00519	CcSEcCtD
Carbinoxamine—Somnolence—Pentoxifylline—systemic scleroderma	0.00146	0.00512	CcSEcCtD
Carbinoxamine—Dyspepsia—Pentoxifylline—systemic scleroderma	0.00145	0.00507	CcSEcCtD
Carbinoxamine—Vision blurred—Captopril—systemic scleroderma	0.00144	0.00504	CcSEcCtD
Carbinoxamine—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.00143	0.00502	CcSEcCtD
Carbinoxamine—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00143	0.005	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Lisinopril—systemic scleroderma	0.00142	0.00496	CcSEcCtD
Carbinoxamine—Constipation—Pentoxifylline—systemic scleroderma	0.00141	0.00492	CcSEcCtD
Carbinoxamine—Chills—Azathioprine—systemic scleroderma	0.00137	0.00481	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Lisinopril—systemic scleroderma	0.00136	0.00475	CcSEcCtD
Carbinoxamine—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.00135	0.00474	CcSEcCtD
Carbinoxamine—Anorexia—Mometasone—systemic scleroderma	0.00135	0.00473	CcSEcCtD
Carbinoxamine—Palpitations—Captopril—systemic scleroderma	0.00135	0.00472	CcSEcCtD
Carbinoxamine—Urticaria—Pentoxifylline—systemic scleroderma	0.00131	0.00457	CcSEcCtD
Carbinoxamine—Chills—Leflunomide—systemic scleroderma	0.0013	0.00454	CcSEcCtD
Carbinoxamine—Agranulocytosis—Lisinopril—systemic scleroderma	0.00129	0.00452	CcSEcCtD
Carbinoxamine—Tinnitus—Mycophenolic acid—systemic scleroderma	0.00129	0.0045	CcSEcCtD
Carbinoxamine—Paraesthesia—Mometasone—systemic scleroderma	0.00127	0.00446	CcSEcCtD
Carbinoxamine—Euphoric mood—Prednisone—systemic scleroderma	0.00126	0.00442	CcSEcCtD
Carbinoxamine—Confusional state—Captopril—systemic scleroderma	0.00126	0.0044	CcSEcCtD
Carbinoxamine—Pollakiuria—Mycophenolate mofetil—systemic scleroderma	0.00126	0.0044	CcSEcCtD
Carbinoxamine—Dyspepsia—Mometasone—systemic scleroderma	0.00125	0.00437	CcSEcCtD
Carbinoxamine—Chills—Mycophenolic acid—systemic scleroderma	0.00124	0.00433	CcSEcCtD
Carbinoxamine—Decreased appetite—Mometasone—systemic scleroderma	0.00123	0.00432	CcSEcCtD
Carbinoxamine—Fatigue—Mometasone—systemic scleroderma	0.00122	0.00428	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Captopril—systemic scleroderma	0.00122	0.00427	CcSEcCtD
Carbinoxamine—Tachycardia—Captopril—systemic scleroderma	0.00122	0.00426	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00416	CcSEcCtD
Carbinoxamine—Anorexia—Captopril—systemic scleroderma	0.00119	0.00416	CcSEcCtD
Carbinoxamine—Vision blurred—Leflunomide—systemic scleroderma	0.00119	0.00415	CcSEcCtD
Carbinoxamine—Asthenia—Pentoxifylline—systemic scleroderma	0.00118	0.00413	CcSEcCtD
Carbinoxamine—Tension—Mycophenolic acid—systemic scleroderma	0.00118	0.00412	CcSEcCtD
Carbinoxamine—Nervousness—Mycophenolic acid—systemic scleroderma	0.00117	0.00408	CcSEcCtD
Carbinoxamine—Hypotension—Captopril—systemic scleroderma	0.00116	0.00408	CcSEcCtD
Carbinoxamine—Tinnitus—Lisinopril—systemic scleroderma	0.00116	0.00405	CcSEcCtD
Carbinoxamine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00113	0.00396	CcSEcCtD
Carbinoxamine—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00396	CcSEcCtD
Carbinoxamine—Vertigo—Leflunomide—systemic scleroderma	0.00113	0.00396	CcSEcCtD
Carbinoxamine—Insomnia—Captopril—systemic scleroderma	0.00113	0.00394	CcSEcCtD
Carbinoxamine—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00112	0.00394	CcSEcCtD
Carbinoxamine—Tremor—Mycophenolic acid—systemic scleroderma	0.00112	0.00394	CcSEcCtD
Carbinoxamine—Paraesthesia—Captopril—systemic scleroderma	0.00112	0.00392	CcSEcCtD
Carbinoxamine—Chills—Lisinopril—systemic scleroderma	0.00111	0.0039	CcSEcCtD
Carbinoxamine—Palpitations—Leflunomide—systemic scleroderma	0.00111	0.00389	CcSEcCtD
Carbinoxamine—Somnolence—Captopril—systemic scleroderma	0.00111	0.00388	CcSEcCtD
Carbinoxamine—Agitation—Mycophenolic acid—systemic scleroderma	0.0011	0.00386	CcSEcCtD
Carbinoxamine—Dyspepsia—Captopril—systemic scleroderma	0.0011	0.00384	CcSEcCtD
Carbinoxamine—Dizziness—Pentoxifylline—systemic scleroderma	0.00109	0.00381	CcSEcCtD
Carbinoxamine—Decreased appetite—Captopril—systemic scleroderma	0.00108	0.00379	CcSEcCtD
Carbinoxamine—Vertigo—Mycophenolic acid—systemic scleroderma	0.00108	0.00377	CcSEcCtD
Carbinoxamine—Fatigue—Captopril—systemic scleroderma	0.00107	0.00376	CcSEcCtD
Carbinoxamine—Constipation—Captopril—systemic scleroderma	0.00107	0.00373	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00106	0.00373	CcSEcCtD
Carbinoxamine—Tension—Lisinopril—systemic scleroderma	0.00106	0.00371	CcSEcCtD
Carbinoxamine—Palpitations—Mycophenolic acid—systemic scleroderma	0.00106	0.00371	CcSEcCtD
Carbinoxamine—Nervousness—Lisinopril—systemic scleroderma	0.00105	0.00368	CcSEcCtD
Carbinoxamine—Vomiting—Pentoxifylline—systemic scleroderma	0.00105	0.00366	CcSEcCtD
Carbinoxamine—Convulsion—Mycophenolic acid—systemic scleroderma	0.00104	0.00364	CcSEcCtD
Carbinoxamine—Headache—Pentoxifylline—systemic scleroderma	0.00103	0.0036	CcSEcCtD
Carbinoxamine—Feeling abnormal—Captopril—systemic scleroderma	0.00103	0.00359	CcSEcCtD
Carbinoxamine—Vision blurred—Lisinopril—systemic scleroderma	0.00102	0.00357	CcSEcCtD
Carbinoxamine—Asthenia—Mometasone—systemic scleroderma	0.00102	0.00356	CcSEcCtD
Carbinoxamine—Irritability—Prednisone—systemic scleroderma	0.00102	0.00356	CcSEcCtD
Carbinoxamine—Hypotension—Azathioprine—systemic scleroderma	0.00102	0.00356	CcSEcCtD
Carbinoxamine—Photosensitivity—Methotrexate—systemic scleroderma	0.00101	0.00355	CcSEcCtD
Carbinoxamine—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00355	CcSEcCtD
Carbinoxamine—Tremor—Lisinopril—systemic scleroderma	0.00101	0.00355	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00101	0.00352	CcSEcCtD
Carbinoxamine—Tachycardia—Leflunomide—systemic scleroderma	0.001	0.00351	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000993	0.00347	CcSEcCtD
Carbinoxamine—Confusional state—Mycophenolic acid—systemic scleroderma	0.000988	0.00346	CcSEcCtD
Carbinoxamine—Anorexia—Leflunomide—systemic scleroderma	0.000979	0.00343	CcSEcCtD
Carbinoxamine—Nausea—Pentoxifylline—systemic scleroderma	0.000976	0.00342	CcSEcCtD
Carbinoxamine—Chills—Mycophenolate mofetil—systemic scleroderma	0.000976	0.00342	CcSEcCtD
Carbinoxamine—Vertigo—Lisinopril—systemic scleroderma	0.000971	0.0034	CcSEcCtD
Carbinoxamine—Diarrhoea—Mometasone—systemic scleroderma	0.000971	0.0034	CcSEcCtD
Carbinoxamine—Hypotension—Leflunomide—systemic scleroderma	0.000959	0.00336	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000959	0.00336	CcSEcCtD
Carbinoxamine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000956	0.00335	CcSEcCtD
Carbinoxamine—Palpitations—Lisinopril—systemic scleroderma	0.000955	0.00334	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000947	0.00331	CcSEcCtD
Carbinoxamine—Anorexia—Mycophenolic acid—systemic scleroderma	0.000934	0.00327	CcSEcCtD
Carbinoxamine—Tension—Mycophenolate mofetil—systemic scleroderma	0.000929	0.00325	CcSEcCtD
Carbinoxamine—Insomnia—Leflunomide—systemic scleroderma	0.000929	0.00325	CcSEcCtD
Carbinoxamine—Paraesthesia—Leflunomide—systemic scleroderma	0.000922	0.00323	CcSEcCtD
Carbinoxamine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00092	0.00322	CcSEcCtD
Carbinoxamine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000915	0.0032	CcSEcCtD
Carbinoxamine—Dyspepsia—Leflunomide—systemic scleroderma	0.000904	0.00316	CcSEcCtD
Carbinoxamine—Vomiting—Mometasone—systemic scleroderma	0.000902	0.00316	CcSEcCtD
Carbinoxamine—Sweating increased—Prednisone—systemic scleroderma	0.000898	0.00314	CcSEcCtD
Carbinoxamine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000896	0.00314	CcSEcCtD
Carbinoxamine—Asthenia—Captopril—systemic scleroderma	0.000894	0.00313	CcSEcCtD
Carbinoxamine—Decreased appetite—Leflunomide—systemic scleroderma	0.000893	0.00312	CcSEcCtD
Carbinoxamine—Confusional state—Lisinopril—systemic scleroderma	0.00089	0.00311	CcSEcCtD
Carbinoxamine—Headache—Mometasone—systemic scleroderma	0.000889	0.00311	CcSEcCtD
Carbinoxamine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000887	0.00311	CcSEcCtD
Carbinoxamine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000886	0.0031	CcSEcCtD
Carbinoxamine—Fatigue—Leflunomide—systemic scleroderma	0.000885	0.0031	CcSEcCtD
Carbinoxamine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00088	0.00308	CcSEcCtD
Carbinoxamine—Constipation—Leflunomide—systemic scleroderma	0.000878	0.00307	CcSEcCtD
Carbinoxamine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000871	0.00305	CcSEcCtD
Carbinoxamine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00087	0.00305	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000864	0.00302	CcSEcCtD
Carbinoxamine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000862	0.00302	CcSEcCtD
Carbinoxamine—Tachycardia—Lisinopril—systemic scleroderma	0.000861	0.00301	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000853	0.00299	CcSEcCtD
Carbinoxamine—Diarrhoea—Captopril—systemic scleroderma	0.000852	0.00298	CcSEcCtD
Carbinoxamine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000852	0.00298	CcSEcCtD
Carbinoxamine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000851	0.00298	CcSEcCtD
Carbinoxamine—Irritability—Methotrexate—systemic scleroderma	0.00085	0.00298	CcSEcCtD
Carbinoxamine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000846	0.00296	CcSEcCtD
Carbinoxamine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000845	0.00296	CcSEcCtD
Carbinoxamine—Nausea—Mometasone—systemic scleroderma	0.000843	0.00295	CcSEcCtD
Carbinoxamine—Anorexia—Lisinopril—systemic scleroderma	0.000841	0.00294	CcSEcCtD
Carbinoxamine—Constipation—Mycophenolic acid—systemic scleroderma	0.000838	0.00293	CcSEcCtD
Carbinoxamine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000837	0.00293	CcSEcCtD
Carbinoxamine—Hypotension—Lisinopril—systemic scleroderma	0.000824	0.00289	CcSEcCtD
Carbinoxamine—Dizziness—Captopril—systemic scleroderma	0.000824	0.00288	CcSEcCtD
Carbinoxamine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000821	0.00287	CcSEcCtD
Carbinoxamine—Urticaria—Leflunomide—systemic scleroderma	0.000816	0.00286	CcSEcCtD
Carbinoxamine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000807	0.00283	CcSEcCtD
Carbinoxamine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000805	0.00282	CcSEcCtD
Carbinoxamine—Insomnia—Lisinopril—systemic scleroderma	0.000798	0.00279	CcSEcCtD
Carbinoxamine—Paraesthesia—Lisinopril—systemic scleroderma	0.000792	0.00277	CcSEcCtD
Carbinoxamine—Vomiting—Captopril—systemic scleroderma	0.000792	0.00277	CcSEcCtD
Carbinoxamine—Somnolence—Lisinopril—systemic scleroderma	0.000784	0.00275	CcSEcCtD
Carbinoxamine—Headache—Captopril—systemic scleroderma	0.00078	0.00273	CcSEcCtD
Carbinoxamine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000779	0.00273	CcSEcCtD
Carbinoxamine—Dyspepsia—Lisinopril—systemic scleroderma	0.000777	0.00272	CcSEcCtD
Carbinoxamine—Decreased appetite—Lisinopril—systemic scleroderma	0.000767	0.00268	CcSEcCtD
Carbinoxamine—Fatigue—Lisinopril—systemic scleroderma	0.000761	0.00266	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000757	0.00265	CcSEcCtD
Carbinoxamine—Constipation—Lisinopril—systemic scleroderma	0.000754	0.00264	CcSEcCtD
Carbinoxamine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000754	0.00264	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000747	0.00262	CcSEcCtD
Carbinoxamine—Diarrhoea—Azathioprine—systemic scleroderma	0.000744	0.0026	CcSEcCtD
Carbinoxamine—Nausea—Captopril—systemic scleroderma	0.00074	0.00259	CcSEcCtD
Carbinoxamine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000737	0.00258	CcSEcCtD
Carbinoxamine—Asthenia—Leflunomide—systemic scleroderma	0.000737	0.00258	CcSEcCtD
Carbinoxamine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000727	0.00255	CcSEcCtD
Carbinoxamine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000722	0.00253	CcSEcCtD
Carbinoxamine—Dizziness—Azathioprine—systemic scleroderma	0.000719	0.00252	CcSEcCtD
Carbinoxamine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000703	0.00246	CcSEcCtD
Carbinoxamine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000703	0.00246	CcSEcCtD
Carbinoxamine—Diarrhoea—Leflunomide—systemic scleroderma	0.000703	0.00246	CcSEcCtD
Carbinoxamine—Urticaria—Lisinopril—systemic scleroderma	0.000701	0.00245	CcSEcCtD
Carbinoxamine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000699	0.00245	CcSEcCtD
Carbinoxamine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000694	0.00243	CcSEcCtD
Carbinoxamine—Vomiting—Azathioprine—systemic scleroderma	0.000691	0.00242	CcSEcCtD
Carbinoxamine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000687	0.00241	CcSEcCtD
Carbinoxamine—Drowsiness—Methotrexate—systemic scleroderma	0.000687	0.0024	CcSEcCtD
Carbinoxamine—Headache—Azathioprine—systemic scleroderma	0.000681	0.00238	CcSEcCtD
Carbinoxamine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00068	0.00238	CcSEcCtD
Carbinoxamine—Dizziness—Leflunomide—systemic scleroderma	0.000679	0.00238	CcSEcCtD
Carbinoxamine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000672	0.00235	CcSEcCtD
Carbinoxamine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00067	0.00235	CcSEcCtD
Carbinoxamine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000661	0.00231	CcSEcCtD
Carbinoxamine—Vomiting—Leflunomide—systemic scleroderma	0.000653	0.00229	CcSEcCtD
Carbinoxamine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000648	0.00227	CcSEcCtD
Carbinoxamine—Nausea—Azathioprine—systemic scleroderma	0.000646	0.00226	CcSEcCtD
Carbinoxamine—Headache—Leflunomide—systemic scleroderma	0.000643	0.00225	CcSEcCtD
Carbinoxamine—Agranulocytosis—Methotrexate—systemic scleroderma	0.000641	0.00224	CcSEcCtD
Carbinoxamine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000637	0.00223	CcSEcCtD
Carbinoxamine—Asthenia—Lisinopril—systemic scleroderma	0.000633	0.00222	CcSEcCtD
Carbinoxamine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000623	0.00218	CcSEcCtD
Carbinoxamine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000614	0.00215	CcSEcCtD
Carbinoxamine—Headache—Mycophenolic acid—systemic scleroderma	0.000614	0.00215	CcSEcCtD
Carbinoxamine—Nausea—Leflunomide—systemic scleroderma	0.00061	0.00213	CcSEcCtD
Carbinoxamine—Vision blurred—Prednisone—systemic scleroderma	0.000605	0.00212	CcSEcCtD
Carbinoxamine—Diarrhoea—Lisinopril—systemic scleroderma	0.000604	0.00211	CcSEcCtD
Carbinoxamine—Agitation—Prednisone—systemic scleroderma	0.00059	0.00207	CcSEcCtD
Carbinoxamine—Dizziness—Lisinopril—systemic scleroderma	0.000583	0.00204	CcSEcCtD
Carbinoxamine—Nausea—Mycophenolic acid—systemic scleroderma	0.000582	0.00204	CcSEcCtD
Carbinoxamine—Vertigo—Prednisone—systemic scleroderma	0.000577	0.00202	CcSEcCtD
Carbinoxamine—Tinnitus—Methotrexate—systemic scleroderma	0.000575	0.00201	CcSEcCtD
Carbinoxamine—Vomiting—Lisinopril—systemic scleroderma	0.000561	0.00196	CcSEcCtD
Carbinoxamine—Convulsion—Prednisone—systemic scleroderma	0.000556	0.00195	CcSEcCtD
Carbinoxamine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000555	0.00194	CcSEcCtD
Carbinoxamine—Chills—Methotrexate—systemic scleroderma	0.000553	0.00194	CcSEcCtD
Carbinoxamine—Headache—Lisinopril—systemic scleroderma	0.000553	0.00193	CcSEcCtD
Carbinoxamine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000529	0.00185	CcSEcCtD
Carbinoxamine—Nausea—Lisinopril—systemic scleroderma	0.000524	0.00183	CcSEcCtD
Carbinoxamine—Tachycardia—Prednisone—systemic scleroderma	0.000511	0.00179	CcSEcCtD
Carbinoxamine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000511	0.00179	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000507	0.00177	CcSEcCtD
Carbinoxamine—Vision blurred—Methotrexate—systemic scleroderma	0.000506	0.00177	CcSEcCtD
Carbinoxamine—Anorexia—Prednisone—systemic scleroderma	0.000499	0.00175	CcSEcCtD
Carbinoxamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000492	0.00172	CcSEcCtD
Carbinoxamine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000484	0.0017	CcSEcCtD
Carbinoxamine—Vertigo—Methotrexate—systemic scleroderma	0.000482	0.00169	CcSEcCtD
Carbinoxamine—Insomnia—Prednisone—systemic scleroderma	0.000474	0.00166	CcSEcCtD
Carbinoxamine—Paraesthesia—Prednisone—systemic scleroderma	0.000471	0.00165	CcSEcCtD
Carbinoxamine—Convulsion—Methotrexate—systemic scleroderma	0.000465	0.00163	CcSEcCtD
Carbinoxamine—Dyspepsia—Prednisone—systemic scleroderma	0.000461	0.00161	CcSEcCtD
Carbinoxamine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00161	CcSEcCtD
Carbinoxamine—Decreased appetite—Prednisone—systemic scleroderma	0.000456	0.00159	CcSEcCtD
Carbinoxamine—Fatigue—Prednisone—systemic scleroderma	0.000452	0.00158	CcSEcCtD
Carbinoxamine—Constipation—Prednisone—systemic scleroderma	0.000448	0.00157	CcSEcCtD
Carbinoxamine—Confusional state—Methotrexate—systemic scleroderma	0.000442	0.00155	CcSEcCtD
Carbinoxamine—Feeling abnormal—Prednisone—systemic scleroderma	0.000432	0.00151	CcSEcCtD
Carbinoxamine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000429	0.0015	CcSEcCtD
Carbinoxamine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000423	0.00148	CcSEcCtD
Carbinoxamine—Anorexia—Methotrexate—systemic scleroderma	0.000417	0.00146	CcSEcCtD
Carbinoxamine—Urticaria—Prednisone—systemic scleroderma	0.000416	0.00146	CcSEcCtD
Carbinoxamine—Hypotension—Methotrexate—systemic scleroderma	0.000409	0.00143	CcSEcCtD
Carbinoxamine—Insomnia—Methotrexate—systemic scleroderma	0.000396	0.00139	CcSEcCtD
Carbinoxamine—Paraesthesia—Methotrexate—systemic scleroderma	0.000393	0.00138	CcSEcCtD
Carbinoxamine—Somnolence—Methotrexate—systemic scleroderma	0.000389	0.00136	CcSEcCtD
Carbinoxamine—Dyspepsia—Methotrexate—systemic scleroderma	0.000385	0.00135	CcSEcCtD
Carbinoxamine—Decreased appetite—Methotrexate—systemic scleroderma	0.000381	0.00133	CcSEcCtD
Carbinoxamine—HRH1—connective tissue—systemic scleroderma	0.000379	0.0359	CbGeAlD
Carbinoxamine—Fatigue—Methotrexate—systemic scleroderma	0.000378	0.00132	CcSEcCtD
Carbinoxamine—Asthenia—Prednisone—systemic scleroderma	0.000376	0.00132	CcSEcCtD
Carbinoxamine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000361	0.00126	CcSEcCtD
Carbinoxamine—Diarrhoea—Prednisone—systemic scleroderma	0.000359	0.00126	CcSEcCtD
Carbinoxamine—CYP2C19—digestive system—systemic scleroderma	0.000358	0.0339	CbGeAlD
Carbinoxamine—CYP2B6—skin of body—systemic scleroderma	0.00035	0.0332	CbGeAlD
Carbinoxamine—Urticaria—Methotrexate—systemic scleroderma	0.000348	0.00122	CcSEcCtD
Carbinoxamine—Dizziness—Prednisone—systemic scleroderma	0.000347	0.00121	CcSEcCtD
Carbinoxamine—HRH1—smooth muscle tissue—systemic scleroderma	0.000346	0.0328	CbGeAlD
Carbinoxamine—Vomiting—Prednisone—systemic scleroderma	0.000333	0.00117	CcSEcCtD
Carbinoxamine—Headache—Prednisone—systemic scleroderma	0.000328	0.00115	CcSEcCtD
Carbinoxamine—Asthenia—Methotrexate—systemic scleroderma	0.000314	0.0011	CcSEcCtD
Carbinoxamine—Nausea—Prednisone—systemic scleroderma	0.000311	0.00109	CcSEcCtD
Carbinoxamine—Diarrhoea—Methotrexate—systemic scleroderma	0.0003	0.00105	CcSEcCtD
Carbinoxamine—Dizziness—Methotrexate—systemic scleroderma	0.00029	0.00101	CcSEcCtD
Carbinoxamine—CYP2B6—digestive system—systemic scleroderma	0.00028	0.0266	CbGeAlD
Carbinoxamine—Vomiting—Methotrexate—systemic scleroderma	0.000278	0.000975	CcSEcCtD
Carbinoxamine—CYP2C9—digestive system—systemic scleroderma	0.000277	0.0263	CbGeAlD
Carbinoxamine—Headache—Methotrexate—systemic scleroderma	0.000274	0.00096	CcSEcCtD
Carbinoxamine—HRH1—digestive system—systemic scleroderma	0.000273	0.0259	CbGeAlD
Carbinoxamine—CYP2E1—digestive system—systemic scleroderma	0.000263	0.0249	CbGeAlD
Carbinoxamine—HRH1—tendon—systemic scleroderma	0.00026	0.0247	CbGeAlD
Carbinoxamine—Nausea—Methotrexate—systemic scleroderma	0.00026	0.000911	CcSEcCtD
Carbinoxamine—CYP2E1—tendon—systemic scleroderma	0.00025	0.0237	CbGeAlD
Carbinoxamine—CYP2B6—lung—systemic scleroderma	0.000234	0.0222	CbGeAlD
Carbinoxamine—HRH1—lung—systemic scleroderma	0.000228	0.0217	CbGeAlD
Carbinoxamine—CYP2E1—lung—systemic scleroderma	0.000219	0.0208	CbGeAlD
Carbinoxamine—CYP3A4—digestive system—systemic scleroderma	0.000211	0.0201	CbGeAlD
Carbinoxamine—CYP2D6—digestive system—systemic scleroderma	0.000208	0.0197	CbGeAlD
